Meetup 12 - 20.03.2019

Risk to Reward: Lessons from leaders in life-sciences

For every decision you make, there is a trade-off.
Reward vs risk. 
Upside vs downside.

Analysing a situation and making the correct decision is the key to success in business whatever stage your company is at. To understand decision-making in the life sciences, we have assembled a panel of industry professionals with over 80 years of experience between them.

Join us to hear about the vital decisions they made during their entrepreneurial journeys.


Registration, networking & drinks 6 pm - 6:45pm

Welcome from SEC and Gallagher 6:45 pm – 7 pm

Panel discussion and debate 7 pm – 8 pm

Further networking and Canapés & Drinks 8 pm – 8:45 pm

The panellists:

We are privileged to have four amazing panellists, with extensive experience in the industry and many insights to share:

Barry Knight:

Barry has more than 25 years of experience as an executive director in life sciences businesses. Before joining EM Imaging he was COO at Kinapse Ltd, an international consulting and outsourcing business servicing the world’s top pharmaceutical companies and Finance Director of Fulcrum Pharma plc, an AIM listed international consultancy. Prior to joining Fulcrum Pharma, Barry was Finance and Administration Director in rapidly growing biotechnology and medical device companies.

Tina Crombie:

Tina has a background in biological sciences and law, project and contract management and intellectual property. She is the co-founder and director of TCR UK Solutions limited and acts as the Head of Business Operations for Advent Bioservices.

Andrew Muncey:

Andrew brings over 30 years’ experience in finance and management to Artios. He previously served as Co-founder and Chief Financial Officer of Acacia Pharma, and Chief Executive Officer of Amura Therapeutics. Andrew has been Chief Financial Officer or Finance Director of several healthcare companies, including MISSION Therapeutics, Bicycle Therapeutics, Kymab, and Virttu Biologics. Andrew has raised significant amounts of equity and debt funding, including $250 million in private equity, and has completed many acquisitions, disposals and restructuring deals in the healthcare market. He has over 15 years’ corporate finance and capital markets experience from PricewaterhouseCoopers and UBS.

Phil Boyd:

Dr. Phil Boyd was CFO of Syntaxin Ltd from through to the acquisition by Ipsen in July 2013. Prior to Syntaxin, he was UK Finance Director of Evotec AG (2001-2007) and Cambridge Discovery Chemistry (1999-2001). He currently serves as CFO with Caldan Therapeutics, Enterprise Therapeutics Ltd and IGEM Therapeutics Ltd, and as a Non-Executive Director with UK BioCentre Ltd. He has a Ph.D. in Genetics.